THERAPEUTIC DILEMMAS: At The Intersection of Environmental Air Pollutant Exposure, Genetic Variation and Asthma Control

Wednesday, May 24, 2017; 2:00 - 3:00 PM ET

Presented by Christopher Reilly, PhD, Associate Professor, Pharmacology and Toxicology, College of Pharmacy, University of Utah

Why is this important to your practice?
Air pollution is a global problem with serious health consequences. The effects of poor air quality on the efficacy of asthma control medications is of great concern for patients with respiratory disorders, their families, and healthcare providers. Exposures environmental or dietary xenobiotics are well recognized to impact drug disposition and response, such as through the induction or interactions with drug metabolizing enzymes or drug transporters. Additionally, drug responsiveness can also be modulated through receptor expression/activity within the cells lining airways. Genetic predisposition among some individuals may cause sensitization to air pollutants and interfere with the expected metabolic clearance of drugs, therefore requiring adaptation of asthma control regimens to treat more effectively an individual’s disease characteristics. This webinar will discuss new findings that connect pulmonary irritant sensing and xenobiotic clearance pathways with variations in asthma control as well as the resulting implications for treatment of asthma.

Target Audience
This webinar is intended for pharmacologists, pharmacists, clinicians or graduate/postgraduate trainees wishing to better understand the implications of environmental contaminants on the activity and efficacy of asthma control medication. This webinar is also suitable for pharmacology/biomedical graduate or medical students who are interested in respiratory disorders, clinical pharmacology, or integrative medicine. Additionally, individuals who are likely to be involved in facilitating patient care such as physician assistants, nursing, and pharmacy professionals may also benefit from this webinar.

Goal and Objectives
After completing this activity, the learner will be able to:

1. Describe the mechanisms by which particulate matter, such as coal fly ash, can stimulate pro-inflammatory signaling cascades within the respiratory tract
2. Discuss the potential consequences of exposure to particulate matter for those who suffer from asthma as it relates to respiratory tract physiology and medical interventions
3. Among individuals with and without asthma, describe how genetic variation in TRP channels may predispose or influence susceptibility to inhaled particulate matter
4. Discuss the ramifications of the findings for asthma control intervention for individuals living in different environments (i.e., different levels of exposure to particulate matter due to proximity to emissions)

Christopher Reilly, PhD is an Associate Professor of Pharmacology and Toxicology and Associate Director of the Center for Human Toxicology at the University of Utah.  He received his PhD in Toxicology (1999) from Utah State University under Dr. Steven D. Aust. Dr. Reilly’s work focused on peroxidase- and oxygen radical-mediated toxicities and enzymatic mechanisms for iron loading and storage in ferritin. Dr. Reilly was a post-doctoral fellow from 1999-2001 at the University of Utah with Dr. Garold S. Yost and the Center for Human Toxicology where he studied mass spectrometry and catalytic mechanisms for the metabolism and bioactivation of xenobiotics by Cytochrome P450 enzymes, pulmonary-selective drug metabolism, and the pulmonary toxicity of pepper sprays. Through this work Dr. Reilly became interested in Transient Receptor Potential cation channels as mediators of xenobiotic toxicities in the lung. His work on the TRP ion channels has evolved and is now focused on interactions between TRP channels and airway inflammation and injury. His group’s work on CYP enzymes and TRP channels has fortuitously intersected leading to new insights on how genetic variations in CYPs and TRPs as well as exposure to environmental pollutants may affect asthma symptom control using traditional therapeutics.

ACPE Accreditation Statement

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. 

• UAN Number:
  Live:  0238-0000-17-024-L01-P
  On Demand: 0238-0000-17-025-H01-P    Expires 5/26/2019
• ACPE 1 Contact Hours
• Knowledge Based Activity

ACCME Accreditation Statement

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Designation Statement
The American College of Clinical Pharmacology designates this journal CE activity for 1 AMA PRA Category 1^TM credit.  Physicians should only claim credit commensurate with the extent of the participation in the activity.

Date of Issuance:  May 24, 2017
Expiration Date:  May 24, 2020

In order to receive CE credit, the learner must score 75% or better on the online post-test; complete an online evaluation and print a certificate.

Moderators:
Catherine Sherwin, PhD, MS, FCP and Jonathan Constance, PhD, are with the University of Utah School of Medicine.  As Moderators of the webinar. They developed the continuing education portion of this activity (target audience, goals and objectives and questions with solutions).  They have nothing to disclose.

Presenter:
Christopher Reilly, PhD is an Associate Professor of Pharmacology and Toxicology and Associate Director of the Center for Human Toxicology at the University of Utah and has nothing to disclose.

High Resolution Personalized Precision Therapeutics

Wednesday, June 14, 2017; 2:00 – 3:00 PM ET 

Presented by Roland Valdes Jr., PhD, Univ of Louisville and Keri Donaldson, MD, PhD, Penn State Coll of Medicine and Milton S. Hershey Medical Ctr

Why is this article important to your practice?
A growing use of medications has led to both polypharmacy and addiction. Novel technologies and pharmacogenetic tools are available to increase the precision and personalization of drug selection. We will review and demonstrate the need for novel predictive algorithms to optimize therapeutic approaches based on pharmacogenetic and related molecular diagnostic testing.   

Target Audience
Clinical pharmacologist providing both research and clinical practice. Practitioners of pharmacology services.

Goal and Objectives
After completing this activity, the learner will be able to:

1. Define the need and availability for personalizing drug therapy using pharmacogenetics and targeted informatics tools
2. Apply novel algorithms based on PGx-testing to increase precision of drug selection and reduce polypharmacy 
3. Demonstrate and compare options for providing targeted selection of drugs to reduce or avoid drug addiction

Roland Valdes Jr., PhD is a Tenured Professor of Pathology and Laboratory Medicine and of Biochemistry and Molecular Biology at the University of Louisville’s School of Medicine. He has held the appointment as Distinguished University Scholar and as Senior Vice-Chairman for the Department of Pathology. He presently serves as Chief of Clinical Chemistry and Toxicology for the University Hospital and as Director of the Clinical Chemistry Postdoctoral Fellowship Program.  Dr. Valdes received his Ph.D. in Molecular Biophysics from the University of Virginia where he also completed postdoctoral training in Biochemistry and in Clinical Chemistry and Toxicology. Prior to his move to Louisville in 1989, Dr. Valdes was on the faculty at Washington University School of Medicine in St. Louis. He is a Diplomat of the American Board of Clinical Chemistry and a Fellow of the National Academy of Clinical Biochemistry.  Dr. Valdes is nationally and internationally recognized as a leader in advancing the profession of clinical chemistry and personalized medicine through his contributions in promoting clinical chemistry as a discipline via the scholarships of clinical service, research, and teaching.  Dr. Valdes has served on numerous federal/national committees such as CLIA and NIH Study Sections, and has served as President of several key professional organizations including the Clinical Ligand Assay Society (CLAS), the National Academy of Clinical Biochemistry (NACB), the Commission for Accreditation in Clinical Chemistry (ComACC), and, most recently, the Association of Clinical Scientists (ACS).  Dr. Valdes has also served on the Board of Directors of the American Association for Clinical Chemistry (AACC) and as a Director on the American Board of Clinical Chemistry (ABCC).  He has received several distinguished scientist and recognition awards from professional organizations such as the AACC, NACB, CLAS, and ACS and has authored more than 260 publications. Dr. Valdes holds several patents and is a pioneer in establishing the application of personalized and precision medicine via laboratory diagnostics by founding the first CLIA-accredited laboratory (PGXL Laboratories) focused on providing pharmacogenetic services. He continues working on developing novel laboratory services to enable the practice of precision/personalized medicine using advanced techniques in clinical chemistry.

Keri Donaldson, MD, PhD is Medical Director and CEO of Prescient Medicine,  His work is fueled by an extensive background in the fields of pathology, genomics, and diagnostics. An active ad hoc reviewer and consultant, Dr. Donaldson has earned a reputation as an innovative member of the medical community and garnered key positions within respected institutions and national committees. Throughout his time with Penn State College of Medicine, he’s served as Assistant Professor of Pathology (also at Hershey Medical Center), Assistant Professor of Public Health Sciences (a joint appointment also at Hershey Medical Center), Assistant Professor of Medicine, and Assistant Professor of Biochemistry. He was certified as a diplomate of both the American Board of Pathology and the National Board of Medical Examiners, and is a frequent guest speaker at regional and national symposia. Dr. Donaldson holds a BS from Pennsylvania State University, an MD from Temple University School of Medicine, and a master of science in clinical epidemiology (MSCE) from the University of Pennsylvania School of Medicine.

Knowledge Based Activity

ACPE Accreditation Statement

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. 

UAN Number:
Live:  0238-0000-17-029-L01-P
On Demand: 0238-0000-17-030-H01-P

ACPE 1 Contact Hours

ACCME Accreditation Statement

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Designation Statement

The American College of Clinical Pharmacology designates this journal CE activity for 1 AMA PRA Category 1^TM credit.  Physicians should only claim credit commensurate with the extent of the participation in the activity.

In order to receive CE credit, the learner must score 75% or better on the online post-test and must complete an online evaluation.

Date of Issuance:  6/14/17
Expiration Date:  6/14/20

In order to receive CE credit, the learner must score 75% or better on the online post-test; complete an online evaluation and print a certificate.

Roland Valdes Jr., PhD, Professor, Univ of Louisville School of Medicine discloses that he receives consulting fees from PGXL Laboratories for being member of the Board of Directors and Univ of Louisville receives Grants from PGXL Laboratories.

THERAPEUTIC DILEMMAS: How to Get Targeted Agents to the Patients Who Need Them.  

Tuesday, July 11^th 2017; 2:00 – 3:00 pm ET

Presented by Joanna Yi, MD, Assistant Professor of Pediatric Hematology/Oncology, Baylor College of Medicine/ Texas Children’s Cancer and Hematology Centers 

Why is this topic important to your practice?
Since the discovery of molecularly targeted agents such as Imatinib, there has been an ever-increasing drive to identify other targeted therapeutics to treat patients with more efficacy and less toxicity.  With the advent of genomic sequencing and more recently other "omics" technologies however, the information known about a patient's tumor has outstripped the physician's ability to prescribe medications precisely targeting all the known "drivers" of that disease. Precision medicine efforts to better match patients with targeted agents and innovative trial designs are underway and will be reviewed. Additionally, other methods to expedite and maximize the translation of targeted agents to patients will be addressed.  This will be illustrated with specific examples, including those from pediatric oncology.

Target Audience
This webinar is intended for pharmacologists, pharmacists, clinicians or graduate/postgraduate trainees wishing to better understand current developments in oncology to match patients with the appropriate molecularly targeted therapeutic agents and innovative trial designs with an emphasis on pediatric malignancies. This webinar is also suitable for pharmacology/biomedical graduate or medical students who are interested in oncology, clinical pharmacology or integrative medicine. Additionally, individuals who are likely to be involved in the facilitating patient care such as physician assistants, nursing and pharmacy professionals may also benefit from this webinar.

Goal and Objectives After completing this activity, the learner will be able to:

1. Identify obstacles blocking the translation of therapeutics in the lab to clinical trials
2. List several strategies to accelerate the translation of therapeutics to clinical trials
3. List reasons why pediatric drug discovery uniquely slower than desired
4. Identify strategies which may aid in mitigating the development of resistance to targeted therapy

Joanna Yi, MD, is an assistant professor of Pediatric Hematology/Oncology at Baylor College of Medicine/ Texas Children’s Cancer and Hematology Centers.  She completed her pediatric hematology/oncology fellowship at Dana-Farber/Boston Children’s Cancer and Hematology Centers, where she trained in the laboratory of James Bradner in epigenetics and chemical biology, focusing on the development of DOT1L inhibitors and BET bromodomain inhibitors.  She is a member of the Center for Drug Discovery at BCM, where she seeks to develop and translate targeted small molecules for challenging pediatric cancers. She serves as an intermediary between Texas Children’s Cancer Center labs to champion targets of interest through the drug screening platforms available at the Center for Drug Discovery, including the DNA-Encoded Technology platform.  Her lab has a specific interest chromatin-modifying small molecules, identifying and assessing top synergistic combinations for development pre-clinically and eventually clinically, and concurrently developing the necessary pharmacodynamics biomarkers for translation of these agents.   She is a member of the Developmental Therapeutics, Leukemia, and Neuroblastoma teams at Texas Children’s, and she will be chairing a first-in-children trial of a BET bromodomain inhibitor through the Children’s Oncology Group.

ACPE Accreditation Statement

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. 

ACPE 1 Contact Hours 

UAN Number: Live:  0238-0000-17-035-L05-P 

UAN Number: On-demand: 0238-0000-17-036-H05-P 

Knowledge Based Activity

ACCME Accreditation Statement

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Designation Statement

The American College of Clinical Pharmacology designates this journal CE activity for 1 AMA PRA Category 1^TM credit.  Physicians should only claim credit commensurate with the extent of the participation in the activity.

In order to receive CE credit, the learner must score 75% or better on the online post-test and must complete an online evaluation.

 

Date of Issuance:  July 11, 2017
Expiration Date:  July 11, 2020

ACCP Virtual Journal Club - 2018 Feb - Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration

Live webinar with the author: February 21, 2018   2:00 – 3:00 PM EST  

On-demand webinar recording:  February 28, 2018 to February 28, 2021

Why is this article important to your practice? 

This article addresses a new dose form and therapeutic application of acetaminophen in multi-trauma patients. 

Target Audience: Physicians, Pharmacists, and other clinicians involved in treating multi-trauma patients. 

Goal and Objectives - After completing this activity, the learner will be able to:

• Describe three potential clinical benefits of acetaminophen in the critically ill patient.
• List the primary hepatic metabolic routes and the reported renal clearance of acetaminophen.
• Describe the serum concentrations of acetaminophen needed to provide an antipyretic effect and analgesia.
• Compare the total daily dose of acetaminophen needed to maintain a serum concentration of 10 ug/ml using multiple dosing and a continuous infusion.  

To receive full credit, learners must pre-read the article located in the "handouts" tab.

See Continuing Education Information in the "handouts" tab for more details.

ACCP 2018 Webinar - How to be a GREAT Journal Peer Reviewer

Live webinar with the Editor-in-Chiefs: June 13, 2018   2:00 – 3:00 PM ET  

On-demand webinar recording:  June 13, 2018 to June 13, 2021

Why is this article important to your practice? 

At the completion of this webinar participants will have a strong understanding and the skills to properly review a scientific manuscript, a professional competency applicable to journal peer reviewing across professions. Topics to be covered include: why one should serve as peer reviewer; the purpose of manuscript reviews; aspects of a great review; when to decline a review; confidentiality; a technical guide for reviews for each section of the manuscript; and writing the review.  

Target Audience: 

Researchers, Physicians, Pharmacists, and other professionals requiring training in the professional competencies of peer reviewing. 

Learning Objectives: 

After completing this activity, the learner will be able to:

1. Describe why the peer review process is important;
2. Explain how to review various sections of a scientific manuscript;
3. Identify elements of writing a review that will be of benefit to the authors and to the Editor of the Journal.

To receive full credit, learners must attend the complete live webinar or view the complete on-demand webinar; pass a post-course assessment with 75% or greater and complete an evaluation.

Attendees Obtain Free CE Credits from ACCP Virtual Journal webinars!

Evaluation of Flexible Tacrolimus Drug Concentration Monitoring Approach in Patients Receiving Extended‐Release Once‐Daily Tacrolimus Tablets

ACCP 2018 Virtual Journal Club Webinars

Live Session: Wednesday, August 8, 2018 from 2:00pm to 3:00pm ET

On Demand: August 8, 2018 to August 8, 2021

Why is this webinar important to you? 

Learners that complete this course will be able to evaluate and apply a flexible tacrolimus concentration monitoring approach in the management of kidney transplant patients receiving extended‐release once‐daily tacrolimus tablets that allows for an extended therapeutic monitoring window based upon utilization of formulas and tools for interpreting drug levels within the expanded window.

---

ACPE Accreditation Statement

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0238-0000-18-035-L/H01-P– ACPE 1 Contact Hours

Activity Type:  Knowledge-based   Format: Live & Home-study   Target Audience: ‘P’

ACCME Accreditation Statement

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this live and enduring CE activity for 1 AMA PRA Category 1^TM credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

---

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants.

Learning Objectives

After completing this activity, the learner will be able to:

• Compare the different pharmacokinetic profiles of immediate release and extended-release once-daily tacrolimus formulations;
• Describe the correlations between tacrolimus concentrations around trough levels and the overall exposure (plasma drug concentration curve/AUC) over a dosing interval;
• Interpret non-standard tacrolimus concentration monitoring results and apply these approaches to dosage monitoring/adjustments plans in patients.

Requirements to Receive Credit

In order to receive CE credit, the learner must register for the educational activity, study the provided journal article, attend the Live webinar or view the on-demand webinar, complete the online learning self-assessment (post-test), complete the online course evaluation and print the certificate.

Disclosures: 

• Author/Faculty:   Timothy Horwedel, MHA, PharmD, BCPS, Transplant Clinical Specialist, Barnes-Jewish Hosp, Dept of Pharmacy, reports a relevant financial relationship (honoraria, grant support) with Veloxis Pharmaceuticals. An independent content review has been completed which finds the article and presentation to be evidence-based, unbiased and non-promotional in nature.
• Author/Faculty:   Patricia West-Thielke, PharmD, Director of Clinical Transplant Research, Univ of Illinois, Dept of Surgery, reports relevant financial relationships (honoraria, grant support) with Veloxis Pharmaceuticals and Astellas Pharma US. An independent content review has been completed which finds the article and presentation to be evidence-based, unbiased and non-promotional in nature.
• Moderator/CE Planner:  Parag Kumar, PharmD, Associate Director Clinical Pharmacology, Otsuka America Pharmaceuticals, has nothing to disclose related to this topic.
• CE Content Reviewer:   Sandeep Kushal, MBBS, MD, Professor and Head, Dayanand Medical College and Hosp, Dept of Pharmacology, has nothing to disclose.

Schedule & Fees

The ACCP webinar programs occur several times per year. Registration for the webinars are required but are free of charge to all learners.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: August 8, 2018

Expiration Date: August 8, 2021

Online Location: https://accp1.org/Members/Cont...

---

ACCP is a Member-focused/Member-driven clinical pharmacology society with

Member Benefits that enhance your professional growth. Join today!

---

Prednisone Pharmacokinetics During Pregnancy and Lactation - On Demand

ACCP Virtual Journal Club Webinars

On Demand: Starting September 20, 2018

---

Why is this webinar important to you? 

Learners that complete this course will be able to describe the movement of prednisone and its metabolite, prednisolone, in the body of females during various stages of pregnancy and lactation, including infant exposure to these agents via breast milk.

Target Audience

Interprofessional team of physicians, pharmacists, PhDs, nurse practitioners and physician assistants. 

Learning Objectives

After completing this activity, the learner will be able to:

• Describe the metabolism of prednisone and prednisolone via interconversion;
• Discuss if prednisone and prednisolone undergo dose-dependent pharmacokinetics during pregnancy;
• Discuss if prednisone and prednisolone undergo concentration-dependent pharmacokinetics during pregnancy;
• Interpret that infant exposure to prednisone and prednisolone via breast milk is minimal.

Requirements to Receive Credit

In order to receive CE credit, the learner must register for the educational activity, study the provided journal article, attend the Live webinar or view the on-demand webinar, complete the online learning self-assessment (post-test), complete the online course evaluation and print the certificate.

---

See CE Info tab for more information on CME and CPE credits.

ACPE Accreditation Statement

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0238-0000-18-037-L/H01-P– ACPE 1 Contact Hours

Activity Type:  Knowledge-based   Format: Live & Home-study   Target Audience: ‘P’

ACCME Accreditation Statement

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this live and enduring CE activity for 1 AMA PRA Category 1^TM credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

---

Requirements to Receive Credit

In order to receive CE credit, the learner must register for the educational activity, study the provided journal article, attend the Live webinar or view the on-demand webinar, complete the online learning self-assessment (post-test), complete the online course evaluation and print the certificate.

Online Location: How to Print CE Certificates

https://accp1.org/documents/CommPartners/ReprintCECertificates.pdf

---

Disclosures: 

Author/Faculty:   Mary F. Hébert, PharmD, FCCP, Professor of Pharmacy and Adjunct Professor of Obstetrics & Gynecology, University of Washington, has nothing to disclosure related to this topic.

 Moderator/CE Planner:  Joseph D. Ma, PharmD, FCP, Professor, Skaggs School of Pharmacy & Pharmaceutical Sciences,Univ of California San Diego, Div of Clinical Pharmacology, has nothing to disclose related to this topic.

 Reviewer:   Francis Achike, MD, PhD, MEd, Professor of Pharmacology, Anesthesiology & Clinical Skills, California Univ of Science & Medicine, has nothing to disclose.

---

Schedule & Fees

The ACCP webinar programs occur several times per year. Registration for the webinars are required but are free of charge to all learners.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

---

Home Study Initial Release and Expiration Dates

Date of Issuance: September 19, 2018

Expiration Date: September 19, 2021

Calcineurin Inhibitor and Nonsteroidal Anti-inflammatory Drug Interaction: Implications of Changes in Renal Function Associated With Concurrent Use - ON DEMAND

ACCP Virtual Journal Club Webinars

Live Session: Wednesday, March 13, 2019 from 2:00-3:00pm ET

On Demand: March 13, 2019 through March 13, 2022

---

Why is this webinar important to you? 

Please join us as we discuss the drug interaction between calcineurin inhibitors (CNI) and non-steroidal anti-inflammatory drugs (NSAID) in hospitalized transplant recipients. Although the renal adverse effects of this drug interaction are widely accepted, evidence supporting them are limited. Additionally, the magnitude of adverse renal effects stemming from this drug interaction are unclear. In order to elucidate more information, a recently published, retroactive research study was conducted. This investigation set out to systematically evaluate the impact and magnitude of changes in renal function in hospitalized transplant recipients exposed to both agents. Changes in serum creatinine, specifically those sufficient to cause acute kidney injury (AKI), were analyzed throughout each patient's hospital stay. This data was used to evaluate the incidence of AKI as well as maximal changes in serum creatinine following concomitant use. Join us as we discuss the results of this investigation and provide more detailed evidence supporting this drug interaction.

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants. 

Learning Objectives

After completing this activity, the learner will be able to:

1) Characterize the effect of CNI and NSAID therapy on serum creatinine;
2) Define AKI occurrence potential within the NSAID class;
3) Identify therapeutic recommendations for the combined use of CNIs and NSAIDs in hospitalized transplant patients;
4) Define changes in excretory renal function between experimental groups.

---

Requirements to Receive Credit

In order to receive continuing medical education (CME) or continuing pharmacy education (CPE) credit, the learner must register for the educational activity, study the provided journal article, attend the Live webinar or view the On Demand webinar, complete the online learning Self-assessment Post-test as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the webinar, Post-test and Evaluation. Contact CE@ACCP1.org with any questions.

---

See CE Info in handouts tab for more information on CME and CPE credits.

Suggestions for Model-informed Precision Dosing to Optimize Neonatal Drug Therapy - On Demand

ACCP Virtual Journal Club Webinars

Live Session: Wednesday, January 30, 2019 from 2:00-3:00pm ET

On Demand: Starting January 30, 2019

---

Why is this webinar important to you? 

Learners that complete this course will understand factors that can influence drug response in premature neonates from a precision medicine perspective. This includes a summary of genetic studies conducted to date in the neonatal population related to drug disposition and response as well as model-based approaches to predict and optimize safe and effective drug exposures.

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants. 

Learning Objectives

After completing this activity, the learner will be able to:

1) Identify factors contributing to variability in drug disposition and response among preterm and term neonates;
2) Describe new strategies that might improve the use of therapeutics in treating critically ill neonates;
3) List barriers to the implementation of precision medicine approaches for critically ill neonates;
4) Define the role and limitations of pharmacogenomic information to guide dosing in neonates.

Requirements to Receive Credit

In order to receive CE credit, the learner must register for the educational activity, study the provided journal article, attend the live webinar or view the On-Demand webinar, complete the online learning Self-assessment Post-event test, complete the online course evaluation and print the certificate within thirty (30) days of completing the webinar.

---

See CE Info in handouts tab for more information on CME and CPE credits.

Welcome to ACCP's The Journal of Clinical Pharmacology (JCP) monthly CE Offerings.
Each month, an article selected by the Editor-in-Chief is available for CE credit.

Instructions and Pricing

JCP Journal CE articles are priced in packages of Jan - Dec for each year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once you register, you have access to all of the articles for the calendar year. If you have an ACCP profile, make sure you have signed in to the ACCP website and then register by clicking the green register button at the top right.

Requirements for Completion

Once you have registered, you can access the articles under the Article tab above. The post-event Self-assessment and evaluation are accessed in your dashboard to the right. CE Certificates are available after the learner has completed the self-assessment and the evaluation. You must print your CE Certificate in order to receive CE credit. CPE data is uploaded into the CPE Monitor at the beginning of the following month.

Registration Assistance

If you have any difficulty registering or do not have an ACCP profile, one must be created before you can register for Journal CE articles. If you do not know if you have a profile, please contact KLevy@ACCP1.org for further information to avoid creating duplicate profiles. Please address all other questions to CE@ACCP1.org  

Accreditation Statements

The American College of Clinical Pharmacology (ACCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Clinical Pharmacology (ACCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

---

Disclosure Information

---

Please see this activities individual, monthly announcements on the Journal of Clinical Pharmacology Journal CE page on the ACCP website. 

---

CE Expires 12/31/2020